SF3B1 and melanoma: Within this subgroup, the prognostic relevance of the molecular classification was evident (log-rank p = 0.009, Fig. 6F): patients with a BAP1 mutation and/or monosomy 3p had a median melanoma-related survival of 5.8 years, while the estimated median survival was not reached in the group of patients with an EIF1AX mutation, SF3B1 mutation and/or disomy 3p.